OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases
Yiqing Zheng, Hejun Li, Ling Chen, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Yiqing Zheng, Hejun Li, Ling Chen, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 11
Showing 11 citing articles:
Pediatric Systemic Lupus Erythematous in COVID-19 Era
Ancuța Lupu, Ingrith Miron, Cristina Gavrilovici, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 272-272
Open Access | Times Cited: 14
Ancuța Lupu, Ingrith Miron, Cristina Gavrilovici, et al.
Viruses (2023) Vol. 15, Iss. 2, pp. 272-272
Open Access | Times Cited: 14
A Review of Inactivated COVID-19 Vaccine Development in China: Focusing on Safety and Efficacy in Special Populations
Lidan Hu, Jingmiao Sun, Yan Wang, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1045-1045
Open Access | Times Cited: 12
Lidan Hu, Jingmiao Sun, Yan Wang, et al.
Vaccines (2023) Vol. 11, Iss. 6, pp. 1045-1045
Open Access | Times Cited: 12
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
Carol Hitchon, Dawn M. E. Bowdish, Gilles Boire, et al.
Vaccines (2024) Vol. 12, Iss. 9, pp. 1061-1061
Open Access | Times Cited: 1
Carol Hitchon, Dawn M. E. Bowdish, Gilles Boire, et al.
Vaccines (2024) Vol. 12, Iss. 9, pp. 1061-1061
Open Access | Times Cited: 1
Cyclosporine may reduce the risk of symptomatic COVID-19 in patients with systemic lupus erythematosus: a retrospective cohort study
Hejun Li, Rose S.Y. Lin, Yanqing Wang, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 11
Open Access | Times Cited: 1
Hejun Li, Rose S.Y. Lin, Yanqing Wang, et al.
Microbiology Spectrum (2024) Vol. 12, Iss. 11
Open Access | Times Cited: 1
Breakthrough COVID-19 After Tixagevimab/Cilgavimab Among Patients With Systemic Autoimmune Rheumatic Diseases
Yumeko Kawano, Xiaosong Wang, Naomi J. Patel, et al.
The Journal of Rheumatology (2023) Vol. 51, Iss. 3, pp. 305-312
Open Access | Times Cited: 3
Yumeko Kawano, Xiaosong Wang, Naomi J. Patel, et al.
The Journal of Rheumatology (2023) Vol. 51, Iss. 3, pp. 305-312
Open Access | Times Cited: 3
Effectiveness of BBIBP-CorV vaccine in preventing SARS-CoV2 infection and severe outcomes in people living with multiple sclerosis: A population-based study
Mahdi Barzegar, Amirreza Manteghinejad, Alireza Afshari-Safavi, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 71, pp. 104548-104548
Open Access | Times Cited: 2
Mahdi Barzegar, Amirreza Manteghinejad, Alireza Afshari-Safavi, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 71, pp. 104548-104548
Open Access | Times Cited: 2
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED Study
Carol Hitchon, Dawn M. E. Bowdish, Gilles Boire, et al.
(2024)
Open Access
Carol Hitchon, Dawn M. E. Bowdish, Gilles Boire, et al.
(2024)
Open Access
Predicting higher risk factors for COVID-19 short-term reinfection in patients with rheumatic diseases: a modeling study based on XGBoost algorithm
Yao Liang, Siwei Xie, Xuqi Zheng, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Yao Liang, Siwei Xie, Xuqi Zheng, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access
Do rheumatic diseases, long‐term glucocorticoids, and immunosuppressant treatment, and vaccination impact the COVID‐19 severity? Insight from a retrospective cohort study
Yi Ma, Chang Wei, Zixi Yi, et al.
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 7
Closed Access
Yi Ma, Chang Wei, Zixi Yi, et al.
International Journal of Rheumatic Diseases (2024) Vol. 27, Iss. 7
Closed Access
Impact of methotrexate treatment on vaccines immunogenicity in adult rheumatological patients – Lessons learned from the COVID-19 pandemic
Jakub Wroński, Marzena Ciechomska, Ewa Kuca-Warnawin
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115254-115254
Open Access | Times Cited: 1
Jakub Wroński, Marzena Ciechomska, Ewa Kuca-Warnawin
Biomedicine & Pharmacotherapy (2023) Vol. 165, pp. 115254-115254
Open Access | Times Cited: 1
Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy
Kauzar Mohamed Mohamed, María Paula Álvarez-Hernández, Carlos Jiménez García, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2418-2418
Open Access | Times Cited: 1
Kauzar Mohamed Mohamed, María Paula Álvarez-Hernández, Carlos Jiménez García, et al.
Biomedicines (2023) Vol. 11, Iss. 9, pp. 2418-2418
Open Access | Times Cited: 1
